VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 49,661 shares of the biopharmaceutical company’s stock, valued at approximately $1,652,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.09% of Agios Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of the stock. Erste Asset Management GmbH lifted its position in shares of Agios Pharmaceuticals by 10.9% during the 1st quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company’s stock valued at $65,439,000 after acquiring an additional 220,000 shares during the period. GW&K Investment Management LLC lifted its position in shares of Agios Pharmaceuticals by 19.6% during the 1st quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock valued at $23,954,000 after acquiring an additional 134,063 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Agios Pharmaceuticals by 145.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company’s stock valued at $21,770,000 after acquiring an additional 440,000 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares during the period. Finally, SCS Capital Management LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter valued at $17,905,000.
Analyst Ratings Changes
AGIO has been the subject of several recent analyst reports. Bank of America dropped their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Zacks Research downgraded Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. HC Wainwright restated a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Scotiabank dropped their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $57.25.
Agios Pharmaceuticals Stock Down 3.9%
Shares of AGIO opened at $41.74 on Thursday. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58. The business has a 50-day simple moving average of $38.78 and a two-hundred day simple moving average of $34.88. The stock has a market cap of $2.43 billion, a PE ratio of 3.79 and a beta of 0.83.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.46 million. On average, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.
Insiders Place Their Bets
In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,085 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares of the company’s stock, valued at $4,529,771.76. This represents a 8.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 3,651 shares of the company’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,482 shares of company stock valued at $864,025 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
See Also
- Five stocks we like better than Agios Pharmaceuticals
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Archer’s Recent String of Victories Signals a New Phase of Growth
- Energy and Oil Stocks Explained
- 3 Key Stocks Boosting Buybacks Amid Improving Fundamentals
- Where to Find Earnings Call Transcripts
- The Best AI for Picking Stocks, Ranked by Performance
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.